Physician profile
Todd Eric Kerner
NPI 1184845943
$6,594.98
in general payments reported to CMS, 2019-2025
30 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 94% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $513 · 2021: $759 · 2022: $1,336 · 2023: $836 · 2024: $360 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Travel and Lodging: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.66 |
| Travel and Lodging | $818.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.32 | 2021-2025 | |
| Abbott Laboratories | $1,525.62 | 2022-2025 | Proclaim, Eterna |
| Pfizer INC. | $1,015.44 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $389.24 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $362.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $288.22 | 2021 | |
| Almatica Pharma LLC | $259.01 | 2022-2023 | Gralise |
| Amgen INC. | $203.01 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $176.17 | 2020-2025 | Dysport |
| Avanir Pharmaceuticals, INC. | $123.16 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $103.64 | 2025 | |
| Allergan, INC. | $86.31 | 2019-2022 | |
| Zyla Life Sciences, INC. | $57.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.52 | 2019-2021 | |
| Alfasigma USA, INC. | $50.72 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50.48 | 2019-2020 | |
| Bioventus LLC | $46.64 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $35.65 | 2025 | Xeomin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.35 | 2022-2023 | Relistor |
| Saluda Medical Americas, INC. | $29.50 | 2025 | Evoke |
| Azurity Pharmaceuticals, INC. | $23.40 | 2023 | Horizant |
| Kaleo, INC. | $18.24 | 2019 | |
| Endo USA, INC. | $16.55 | 2025 | Xiaflex |
| Ultragenyx Pharmaceutical INC. | $15.04 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.48 | 2020 | |
| Depuy Synthes Sales INC. | $13.31 | 2024 | Orthovisc, Monovisc |
| Ferring Pharmaceuticals INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.